Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.46 |
| ▸ | KDR | P35968 | 6/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.42 |
| ▸ | RAF1 | P04049 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601549 | 0.80 | KDR (0.54) | BRAFKDRBRD4MAPK14TNNI3K | |
| SCHEMBL13408250 | 0.79 | KDR (0.65) | BRAFKDRMAPK14TNNI3KRAF1 | |
| SCHEMBL3588092 | 0.76 | NPC1 (0.51) | BRAFKDRBRD4MAPK14TNNI3K | |
| SCHEMBL3589751 | 0.72 | KDR (0.53) | BRAFKDRMAPK14TNNI3KRAF1 | |
| SCHEMBL3670190 | 0.71 | HIF1A (0.48) | KDRRAF1 | |
| SCHEMBL3589289 | 0.71 | BRAF (0.60) | BRAFKDRMAPK14TNNI3KRAF1 | |
| SCHEMBL12832428 | 0.70 | HRH4 (0.47) | — | |
| SCHEMBL32680298 | 0.69 | HRH4 (0.44) | RAF1 | |
| SCHEMBL3596312 | 0.69 | NPC1 (0.50) | KDRRAF1 | |
| SCHEMBL13408255 | 0.68 | BRAF (0.49) | BRAFKDRMAPK14TNNI3KRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643991-B1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-7691870-B2 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885KDR 843/4885BRD4 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.